newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Devdiscourse
In an effort to make complex biologic medicines more affordable, the FDA proposed easing rules for biosimilar drug testing.
The FDA has proposed loosening biosimilar drug testing rules to lower costs for complex biologic medicines.
KEY POINTS
Biologic medicines account for over half of drug spending but represent only 5% of prescriptions.
Spanish researchers created an artificial cornea from fish scales as a cheaper alternative to donor transplants.
China disputes U.S. accusations about insufficient control of fentanyl precursor sales during a UN meeting.
In an effort to make complex biologic medicines more affordable, the FDA proposed easing rules for biosimilar drug testing. This initiative targets high-cost treatments for cancer and autoimmune diseases, currently dominating over half of the market's drug spending, despite comprising just 5% of prescriptions.
At a United Nations meeting, the United States and China engaged in a heated exchange, with accusations from Washington that Beijing is lax on controlling fentanyl precursor sales. China refuted the claims, intensifying tensions ahead of a planned diplomatic meeting at the month's end.
Spanish researchers have pioneered an innovative artificial cornea using fish scales, offering a lower-cost substitute for traditional donor transplants used to treat severe eye diseases. The scarcity of donor corneas makes this breakthrough particularly significant in addressing the pressing demand.